Steven Swift to Muscarinic Antagonists
This is a "connection" page, showing publications Steven Swift has written about Muscarinic Antagonists.
Connection Strength
0.760
-
Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study. Clin Drug Investig. 2009; 29(5):305-16.
Score: 0.310
-
A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Feb; 14(1):50-4; discussion 54-5.
Score: 0.206
-
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013 Aug; 112(3):373-85.
Score: 0.106
-
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010 Jan; 105(1):58-66.
Score: 0.083
-
Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol. 2004 Feb; 171(2 Pt 1):752-6.
Score: 0.055